Chemistry:Itasetron

From HandWiki

Itasetron (INN, USAN; developmental code names DAU-6215 and U-98079) is a selective serotonin 5-HT3 receptor antagonist which was under development for the treatment of anxiety disorders, cognition disorders, nausea and vomiting, and psychotic disorders but was never marketed.[1][2][3][4] It is taken orally.[1] Itasetron was first described in the scientific literature by 1990.[5] The drug was under development by Boehringer Ingelheim.[1][2][3] It reached phase 3 clinical trials for nausea and vomiting and phase 2 trials for anxiety disorders.[1][3]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "Itasetron". 22 July 2011. https://adisinsight.springer.com/drugs/800001482. 
  2. ↑ 2.0 2.1 "Delving into the Latest Updates on Itasetron with Synapse". 16 May 2026. https://synapse.patsnap.com/drug/510b30501f7043bd90f9376fabac5c3a. 
  3. ↑ 3.0 3.1 3.2 "Itasetron. DAU 6215, U 98079". Drugs in R&D 2 (4): 243–244. October 1999. doi:10.2165/00126839-199902040-00003. PMID 10659399. 
  4. ↑ "Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation". Cancer Chemotherapy and Pharmacology 28 (6): 470–474. 1991. doi:10.1007/BF00685825. PMID 1834359. 
  5. ↑ "Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists". Journal of Medicinal Chemistry 33 (8): 2101–2108. August 1990. doi:10.1021/jm00170a009. PMID 1695682. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Itasetron&oldid=4582147"